Searched for
GLENMARK ISB 2001
Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...- Indian pharma may take AI pill to cut time and costs in drug R&DIndian pharmaceutical giants Sun Pharma and Glenmark are embracing Artificial Intelligence to speed up new drug creation. This technology p...
- Glenmark Q3 profit rises 16% on strong India, US performanceGlenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performan...
- Glenmark shares gain 2% as firm receives $700 million upfront payment from AbbVie dealGlenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agre...
- Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&PS&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVi...
- Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugsGlenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio a...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investorsThe shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Stocks in news: DMart, IREDA, TCS, ZEE, HUL, Glenmark PharmaMarkets declined on weekly expiry day, with several companies in focus due to earnings and news. TCS reported a 6% profit increase, while I...
- Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug dealGlenmark Pharma Share Price: Glenmark Pharmaceuticals' shares soared after its subsidiary, Ichnos Glenmark Innovation, inked a global licen...
- Glenmark, AbbVie ink $700 million drug licensing dealGlenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...
- Glenmark’s blood cancer drug ISB 2001 shows promising results in trialIchnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating...
- Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drugGlenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated ...
- US prospects, new drugs make Glenmark look betterGlenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...
- Stocks to buy: L&T remains BNP Paribas' top pick; HSBC upgrades Glenmark to buyNomura, BNP Paribas, and HSBC have issued updated recommendations on Shree Cement, Larsen & Toubro (L&T), and Glenmark Pharma, emphasizing ...
- Hot Stocks: 4 stocks that may give returns between 17-27%Analysts recommend stocks such as HDFC Bank, Glenmark Pharmaceuticals, Tata Steel, and Samvardhana Motherson, expecting returns between 17%...
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...
- Glenmark Pharma shares in focus as company swings back to profit in Q3Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...
- Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35%Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY...
Load More
